First patients test new cancer drug as last hope
NCT ID NCT05586321
Summary
This was the first-ever study in people of a new cancer drug called GEN1056. It tested the drug's safety and aimed to find the right dose for future studies in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to see how safe the drug was and if it showed any signs of helping shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ARENSIA Exploratory Medicine LLC
Tbilisi, Georgia
-
ARENSIA Exploratory Medicine Phase I Unit
Chisinau, Moldova
-
Centro Integral Oncologico Clara Campal
Madrid, Spain
-
Clinica Universidad de Navarra
Pamplona, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
-
MD Anderson Cancer Centre
Madrid, Spain
Conditions
Explore the condition pages connected to this study.